Article Text

Download PDFPDF
Pridinol for cancer-related myofascial pain
  1. Séamus Coyle1,2
  1. 1 Liverpool Head and Neck Centre, University of Liverpool, Liverpool, UK
  2. 2 Palliative Medicine, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK
  1. Correspondence to Dr Séamus Coyle, Liverpool Head and Neck Centre, University of Liverpool, Liverpool L3 9TA, UK; s.coyle{at}


Myofascial pain is an important yet under recognised component of cancer pain. It has a prevalence of between 11.9 and 44.8% in cancer patients. Treatments for myofascial pain reduce the prevalence of myofascial trigger points therefore decreasing pain and improving range of motion. Pridinol is a nonbenzodiazepine antispasmodic licenced for the treatment of central and peripheral muscle spasms in adults. This paper describes two case histories where patients with myofascial pain were successfully treated with pridinol. These cases highlight the importance of treating myofascial pain and the potential of pridinol to treat cancer-related myofascial pain.

  • Pain
  • Cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Not applicable.

  • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.